Drug interaction study reveals how itraconazole and rifampin alter HMPL-453 levels

NCT ID NCT07697157

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates how two common drugs—itraconazole (a CYP3A and P-gp inhibitor) and rifampin (a CYP enzyme inducer)—affect the levels of HMPL-453 in the blood of healthy adults. Forty participants will take HMPL-453 alone and then with each of these drugs to see how they change drug exposure and safety. The goal is to guide future dosing recommendations for patients who may need HMPL-453 alongside other medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HMPL-453 tartrate tablets
What this could lead to
If successful, this study could help determine safe and effective dosing of HMPL-453 when taken with common drugs that affect liver enzymes.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. The results may not predict effects in people with the target disease, and drug interactions could increase side effects or reduce effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTH, SUBJECTIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • yijishan Hospital

    Wuhu, Anhui, 241000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.